182 studies found for:    Open Studies | "Blood Platelet Disorders"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Blood Platelet Disorders"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Thrombocytopathy in Gaucher Disease Patients
Conditions: Gaucher Disease;   Thrombocytopathy
Intervention:
2 Recruiting A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Conditions: Primary Myelofibrosis;   Thrombocythemia, Essential;   Thrombocytosis;   Myeloproliferative Disorders;   Bone Marrow Diseases;   Hematologic Diseases;   Blood Coagulation Disorders;   Blood Platelet Disorders;   Hemorrhagic Disorders
Interventions: Drug: LDE225;   Drug: INC424
3 Recruiting Effects of Exercise Training on Cardiovascular Health in Middle-aged Women
Conditions: Menopause;   Cardiac Function Impaired;   Cardiovascular Diseases;   Blood Platelet Disorders;   Metabolic Diseases
Interventions: Behavioral: Yoga/Pilates;   Behavioral: Spinning
4 Not yet recruiting Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder
Condition: Inherited Platelet Disorders
Intervention: Other: Blood collection for platelet protein samples
5 Recruiting Platelet Function in Minimal Extracorporeal Circulation in CABG
Condition: Thrombocytopathy
Interventions: Device: Mini extracorporeal circulation;   Device: Conventional extracorporeal circulation
6 Recruiting Safety and Efficacy of Eltrombopag at Escalated Doses
Conditions: Immune Thrombocytopenia;   Platelet Disorder
Interventions: Drug: Eltrombopag;   Drug: Placebo
7 Recruiting Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Momelotinib
8 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
9 Recruiting ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
Condition: Immune Thrombocytopenia
Intervention: Drug: Second Line ITP agents
10 Recruiting Evaluation of a New Approach of the Diagnosis of Constitutional Functional Disorders of Platelets
Condition: Platelet Dysfunction
Intervention: Other: Blood punction
11 Recruiting A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
12 Recruiting Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Paroxysmal Nocturnal Hemoglobinuria;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Polycythemia Vera;   Primary Myelofibrosis;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis
Interventions: Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
13 Unknown  Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Condition: Autoimmune Thrombocytopenic Purpura
Intervention: Drug: Doxil
14 Recruiting A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Eltrombopag;   Drug: IVIG infusion
15 Recruiting Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Condition: Thrombocytopenia Associated With Liver Disease
Interventions: Drug: avatrombopag (lower baseline platelet count);   Drug: placebo (lower baseline platlet count);   Drug: avatrombopag (higer baseline platelet count);   Drug: placebo (higher baseline platelet count)
16 Not yet recruiting Octaplas Adult TTP Trial
Condition: Thrombotic Thrombocytopenic Purpura
Intervention: Biological: Octaplas
17 Recruiting Myeloproliferative Neoplasms and Bone Structure
Conditions: Polycythemia Vera;   Thrombocythemia, Essential;   Primary Myelofibrosis
Intervention:
18 Recruiting A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Interventions: Drug: Cyclosporin A;   Drug: rhTPO
19 Recruiting Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
Condition: Immune Thrombocytopenic Purpura
Intervention: Drug: Rituximab
20 Recruiting Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Condition: Immune Thrombocytopenic Purpura
Intervention: Drug: Fostamatinib Disodium

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years